Evidence map›Paper›PMID 34943049›Full record

ArticleAntioxidants (Basel, Switzerland)2021

The Relationship between Ozone and Human Blood in the Course of a Well-Controlled, Mild, and Transitory Oxidative Eustress.

Gerardo Tricarico, Valter Travagli

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06706544 phase2 / phase3recruitingnot on this mapstarted 2025, after this paper: background citation

Effectiveness and Cost-effectiveness of Ozone Treatment in Patients With Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (OzoParQT)

TypeinterventionalSponsorBernardino Clavo, MD, PhDRan2025 to 2030Enrolled42ConditionsChemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia, Numbness, TinglingArmsOzone therapy, Oxygen (placebo)
NCT06799351 phase2 / phase3recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluation of the Gut Microbiome Profiles in Patients with Chemotherapy-induced Peripheral Neuropathy Treated in the Randomized Clinical Trial with Ozone OzoParQT (NCT06706544).

TypeinterventionalSponsorBernardino Clavo, MD, PhDRan2025 to 2030Enrolled42ConditionsChemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia, Numbness, TinglingArmsOzone therapy, Oxygen (placebo)
NCT06816095 recruitingnot on this mapstarted 2025, after this paper: background citation

Gene and Molecular Pathway Characterization of the Response to Ozone Treatment in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Radio-chemotherapy

TypeobservationalSponsorBernardino Clavo, MD, PhDRan2025 to 2027Enrolled40ConditionsChronic Pelvic Pain Syndrome (CPPS), Radiation-Induced Disorder, Radiotherapy Side Effects, Side Effect of Chemotherapy
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Evaluation of targeted oxidative stress induced by oxygen-ozoneRedox report : communications in free radical research · 2022
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Gerardo TricaricoPresidio Ospedaliero Sant'Andrea, 13100 Vercelli, Italy.
Valter TravagliDipartimento di Biotecnologie, Chimica e Farmacia-Dipartimento di Eccellenza Nazionale 2018-2022, Università degli Studi di Siena, 53100 Siena, Italy.ORCID 0000-0002-7574-4456
Presidio Ospedaliero · ITUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the last twenty years there has been a proliferation of articles on the therapeutic use of ozone. As it is well-known, the term ozone therapy is very broad. It ranges from either systemic or loco-regional administration of unstable gaseous oxygen/ozone mixtures to the topical application of stable ozonated derivatives. Anyway, in relation to the absence of specific receptors and the extreme reactivity with the biological liquids with which it comes into contact, gaseous ozone cannot be classified as either a drug or a pro-drug. When the gaseous ozone impacts a biological matrix, both reactive oxygen species (ROS) and lipid oxidation products (LOPs) are formed. They represent the effector molecules responsible for modulating the therapeutic activity in the body. Apart from the merits of the action mechanisms resulting from the use of ozone, this article seeks to validate the practice of ozone therapy as an adjuvant treatment in full compliance with the physiology of the whole organism.

Indexed as

bloodimmunomodulationlipid ozonation productsoxidative stressoxidative therapiesozone therapyreactive oxidative species

Identifiers

PMID34943049
PMCPMC8750071
OpenAlexW4200363431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.